Why Wealthy Investors Are Quietly Betting Big on AI and HealthTech

Jan de Vries · 2026-10-12

Investment ambitions across the EU for AI and HealthTech are expansive. The EU's InvestAI initiative aims to mobilize roughly $216 billion for artificial intelligence, including funding for major AI infrastructure. That's not pocket change — it's a statement about where Europe thinks the future is headed. The European Commission and the European Investment Bank Group have also launched BioTechEU to mobilize about $10.8 billion for biotech and life sciences in 2026 and 2027. And that public investment push is happening alongside a quieter trend: AI and healthcare are becoming increasingly popular among wealthy private investors globally. The UBS Global Family Office Report 2026 found that 65% of family offices were already invested in AI, and 33% were allocated to AI-enabled healthcare. So why is so much private capital moving toward AI and HealthTech? Let's dig in. ### Investing in AI and HealthTech in 2026 The scale of the EU's investment and infrastructure plans shows how strategically important AI has become. Infrastructure is one of the clearest examples. In July 2026, the EU requested up to seven AI Gigafactories, backed by up to $10.8 billion in EU and national funding and expected to unlock at least $21.6 billion in additional private investment across the Union. Life sciences are also an important part of the EU economy, already contributing nearly $1.6 trillion in value and supporting 29 million jobs. The EU is now trying to increase investment further through initiatives such as BioTechEU, which is designed to mobilize about $10.8 billion for biotechnology and life sciences investment during 2026 and 2027. The European Commission's wider life sciences strategy also includes measures to make it easier to fund multi-country clinical trials and about $324 million to stimulate the procurement of life sciences innovations, including next-generation vaccines and affordable cancer solutions. As investment moves into high-growth sectors, investors can also explore private-market opportunities through firms operating across venture capital, private equity, and real estate markets. ### AI and HealthTech Sector Growth The EU has a massive life sciences industry with major research institutions, healthcare systems, and rapidly expanding AI infrastructure, which helps explain investor interest. By April 2026, 19 AI Factories had been deployed across European supercomputers, supported by 13 regional AI Factory antennas, giving researchers, startups, and businesses greater access to AI computing capacity. EU and participating EuroHPC countries have committed more than $2.8 billion to the AI Factories and Antennas initiative. Then you've got the healthcare side. The European Health Data Space is designed to make health data easier to access and reuse securely across the EU for research, innovation, and regulatory purposes, creating potentially valuable infrastructure for areas such as medical research and AI development. Other EU projects include building specialist datasets, including Cancer Image Europe, which is expected to provide access to 60 million cancer images by the end of 2026, and the 1+ Million Genomes initiative, which aims to provide secure access to genomic and associated clinical data. Interestingly, the EU is also trying to move AI from research into clinical settings. In 2026, the European Commission made about $9.7 million available for two large-scale pilots of AI-powered medical imaging, covering technologies such as X-rays, CT scans, MRI, PET, and ultrasound. For investors, the attraction is that HealthTech is moving beyond laboratory research into real-world clinical testing and EU-backed deployment programs. ### Massive Capital Rotation From High-Net-Worth Investors It's difficult to track exactly what every high-net-worth individual is investing in. Much private investment isn't publicly disclosed. Family offices tell us they're watching the same signals everyone else is: government money, infrastructure, and proof that the technology works outside a lab. When public funding de-risks a sector, private capital tends to follow. Here's the short version of what's driving the shift: - Public funding is de-risking AI and biotech infrastructure at an unusual scale - HealthTech is moving from research into real clinical pilots - Data infrastructure like Cancer Image Europe and 1+ Million Genomes makes AI development more viable - Family offices are already heavily allocated and looking for the next layer of growth As one family office advisor put it: "We're not chasing hype anymore. We're following the infrastructure." That's the real story here. It's not just about AI being trendy — it's about governments building the roads that private capital wants to drive on.